Yet, a further incentive for investigating mutant COTI-2 as a potential therapy for TN breast cancer is that p53 is mutated in approximately 80% [14, 15] and MYC is amplified in up to 60% of patients with this molecular form of breast cancer [40, 41]. This evidence concerns the gene TP53 and breast carcinoma.